Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Gilead Sciences (GILD) recently underperformed the market with a 2.7% daily loss, despite a 1.14% monthly gain. Ahead of its upcoming earnings, the company is projected for a slight quarterly EPS decline to $2.00 but a revenue increase to $7.03 billion, while full-year EPS is forecast to jump 71.86% to $7.94. Analyst sentiment remains positive, with recent EPS estimate revisions up 0.29% and a Zacks Rank #2 (Buy). Furthermore, GILD appears undervalued, trading at a Forward P/E of 14.12 and PEG ratio of 0.72, significantly below industry averages of 17.7 and 1.5 respectively, suggesting potential upside.

Analysis

Gilead Sciences (GILD) exhibited near-term weakness, closing down 2.7% and underperforming the S&P 500, despite having gained 1.14% over the past month to outperform its sector's 1.56% loss. The market's focus is now on the upcoming earnings release, which presents a mixed near-term outlook with a projected 0.50% year-over-year decline in EPS to $2.00, alongside a 1.07% rise in revenue to $7.03 billion. However, the full-year forecast is substantially more bullish, with analysts expecting EPS to surge 71.86% to $7.94. This positive long-term outlook is reinforced by recent analyst sentiment, as the consensus EPS projection has been revised 0.29% higher in the last 30 days, contributing to a Zacks Rank of #2 (Buy). From a valuation perspective, GILD appears attractive, trading at a Forward P/E of 14.12 and a PEG ratio of 0.72, which represent significant discounts to its industry averages of 17.7 and 1.5, respectively, suggesting the stock may be undervalued relative to its peers and its own earnings growth potential.

Key Decisions for Investors

• Given the strong full-year EPS growth forecast of over 71%, positive analyst estimate revisions, and a valuation discount to its industry on both P/E and PEG metrics, the recent share price dip could represent a compelling entry point.
• Investors should closely monitor the upcoming earnings report for confirmation of the modest revenue growth and, more importantly, for management's commentary justifying the significant full-year earnings expansion.
• Consider the conflicting signals between the stock's recent daily underperformance and slight quarterly EPS decline against the strong longer-term fundamental picture when sizing a position, as near-term volatility may persist leading into the earnings release.